New Mexico Educational Retirement Board reduced its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 3.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 108,685 shares of the company’s stock after selling 3,800 shares during the quarter. Johnson & Johnson accounts for 0.6% of New Mexico Educational Retirement Board’s investment portfolio, making the stock its 18th biggest holding. New Mexico Educational Retirement Board’s holdings in Johnson & Johnson were worth $20,152,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also modified their holdings of JNJ. SOA Wealth Advisors LLC. grew its position in Johnson & Johnson by 0.7% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock valued at $1,371,000 after buying an additional 53 shares during the last quarter. Ethos Financial Group LLC raised its position in Johnson & Johnson by 0.6% during the 3rd quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock worth $1,689,000 after buying an additional 53 shares during the last quarter. Pinnacle Holdings LLC lifted its stake in shares of Johnson & Johnson by 0.5% in the 3rd quarter. Pinnacle Holdings LLC now owns 11,214 shares of the company’s stock worth $2,079,000 after acquiring an additional 54 shares during the period. Bouchey Financial Group Ltd boosted its holdings in shares of Johnson & Johnson by 0.8% in the third quarter. Bouchey Financial Group Ltd now owns 7,249 shares of the company’s stock valued at $1,344,000 after acquiring an additional 54 shares in the last quarter. Finally, Intrepid Capital Management Inc. boosted its holdings in shares of Johnson & Johnson by 0.4% in the third quarter. Intrepid Capital Management Inc. now owns 12,785 shares of the company’s stock valued at $2,371,000 after acquiring an additional 54 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.
Insiders Place Their Bets
In related news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 1,322 shares of Johnson & Johnson stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. This represents a 4.94% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 30,142 shares of company stock worth $7,360,528. Corporate insiders own 0.16% of the company’s stock.
Trending Headlines about Johnson & Johnson
- Positive Sentiment: FDA approval of Icotyde opens a new, convenient oral IL‑23R treatment for moderate‑to‑severe plaque psoriasis — a potential multi‑billion‑dollar growth driver that directly expands J&J’s immunology portfolio and pressures injectable rivals. FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
- Positive Sentiment: HSBC raised its J&J price target to $280 and reiterated a Buy, citing healthcare strength — a clear bullish signal that can support further upside. HSBC Raises Johnson & Johnson (NYSE:JNJ) Price Target to $280.00
- Positive Sentiment: Morgan Stanley and other analysts continue to back J&J’s growth outlook around Icotyde (Morgan Stanley kept a Buy and $262 PT), reinforcing bullish institutional sentiment. Early Icotyde Approval Strengthens Johnson & Johnson’s Immunology Growth Outlook and Multi‑Billion‑Dollar Potential
- Positive Sentiment: Positive analyst/commentary pieces (e.g., The Motley Fool) argue J&J’s diversified franchises and new drugs justify a buy-and-hold stance, supporting longer‑term investor interest. 2 Reasons to Buy Johnson & Johnson Stock Like There’s No Tomorrow
- Neutral Sentiment: Barclays raised its target to $234 but kept an Equal‑Weight rating, implying limited near‑term upside from that shop and signaling mixed views across brokers. Benzinga
- Neutral Sentiment: Online investor interest and searches for JNJ have spiked (Zacks notes heavy attention), which can increase volatility but doesn’t guarantee direction. Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
- Neutral Sentiment: General dividend-planning content (e.g., pieces on how much to invest to get $100k in dividends) may drive some investor interest in JNJ’s yield, but it’s not a company‑specific catalyst. How Much Do you Need To Invest to Make $100k On Dividends Right Now?
- Negative Sentiment: Market/macro skepticism is limiting upside: commentators like Jim Cramer note J&J “should have gone higher” but broader stagflation concerns and a tough tape are keeping buyers cautious, which can cap short‑term gains. Jim Cramer on Johnson & Johnson: “It Should Have Gone Higher, But It Just Shows You How Hard It Is to Buck Stagflation Theories”
- Negative Sentiment: Recent short-term weakness (coverage noting a recent slide) highlights vulnerability to market rotation and headline-driven volatility despite fundamental wins. Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade
Wall Street Analyst Weigh In
Several research analysts recently issued reports on JNJ shares. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Argus boosted their target price on Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. Wolfe Research raised their price target on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a report on Monday, January 5th. Finally, UBS Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $236.91.
Read Our Latest Analysis on JNJ
Johnson & Johnson Stock Up 0.2%
JNJ stock opened at $237.76 on Friday. The company’s 50 day simple moving average is $234.59 and its 200-day simple moving average is $207.97. The firm has a market capitalization of $572.68 billion, a PE ratio of 21.52, a P/E/G ratio of 2.34 and a beta of 0.34. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $251.71. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion during the quarter. Equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date was Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 47.06%.
Johnson & Johnson Profile
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
See Also
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
